EXTON, Penn.--(BUSINESS WIRE)--BioTrends Research Group, LLC finds that, while surveyed neurologists are almost unanimous in reporting that the unique mode of administration of Novartis’s Gilenya is ...

The digital press release with multimedia content can be accessed here: Basel, April 29, 2014 - Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) has issued a ...

“For the first time, we have an FDA-approved treatment specifically for children and adolescents with multiple sclerosis,” explains Billy Dunn, M.D., director of the Division of Neurology Products in ...

The FDA has issued a safety warning that patients who stopped taking Gilenya experienced worsening of multiple sclerosis, compared with before treatment started or during treatment, in rare cases.

Gilenya is the first approved once-daily oral therapy for the treatment of relapsing forms of multiple sclerosis (MS). It was observed in the study that Gilenya was effective against key measures of ...

Novartis International AG / New analysis indicates that Novartis drug Gilenya shows significant early effect on reducing brain volume loss at 6 months . Processed and transmitted by Thomson Reuters ...

Dagmar Rosa-Bjorkeson leads the MS business unit at Novartis, which three years ago this month launched the first of a new wave of MS capsules, Gilenya. This year marked the start of a consumer ...

EXTON, Penn.--(BUSINESS WIRE)-- BioTrends Research Group, LLC finds that, while surveyed neurologists are almost unanimous in reporting that the unique mode of administration of Novartis’s Gilenya is ...